Structure-Based Discovery of Dual PD-L1 and IDO1 Small-Molecule Inhibitors for Non-Small Cell Lung Cancer
- 17 June 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (6) , 612
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancerMedicinal Research Reviews, 2024
- Lung cancer statistics, 2023Cancer, 2024
- Physicochemical properties, drug likeness, ADMET, DFT studies, and in vitro antioxidant activity of oxindole derivativesComputational Biology and Chemistry, 2023
- Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)Cancer, 2019
- Targeting autophagy using natural compounds for cancer prevention and therapyCancer, 2019
- Crucial motifs and residues in the extracellular loops influence the formation and specificity of connexin dockingBiochimica et Biophysica Acta (BBA) - Biomembranes, 2018
- CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small moleculesJournal of Computational Chemistry, 2017
- Molecular dynamics and Monte Carlo simulations for protein–ligand binding and inhibitor designBiochimica et Biophysica Acta (BBA) - General Subjects, 2015
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Flexible Ligand Docking with GlideCurrent Protocols in Bioinformatics, 2007